NuProbe Global Secures $50 Million Series B Funding to Advance Core Molecular Diagnostics Technologies

Recently, NuProbe Global, a genomics and molecular diagnostics company with multiple core patented technologies and a leader in ultra-high-sensitivity tumor gene detection and genetic testing for infertility, announced the completion of its $50 million Series B financing round.

This funding round was co-led by the AstraZeneca CICC Healthcare Industry Fund, the China Resources Zhengda Life Sciences Fund, and existing shareholder Panlin Capital, with participation from Haoren Capital, Deguan Asset Management, and Pappas Capital. Existing shareholders Boyuan Capital, Sequoia Capital, Yonghua Investment, and Tuobang Capital continued to participate in the follow-on investment.

Capital Link served as the exclusive financial advisor to NuProbe Global in this transaction.

"This round of financing will be used to continue advancing NuProbe Global's R&D in leading nucleic acid detection underlying technologies, accelerate the development of new genetic testing products, further expand its commercial teams in the United States and China, and continuously promote the regulatory approval of multiple clinical products."

Just one year after completing its $42 million Series A financing round in 2021, NuProbe Global has once again secured investment from multiple renowned institutions, fully demonstrating the capital market’s strong recognition of the company’s innovative R&D capabilities, technological barriers, and commercial operational progress.

Chai Yingshuang, Chairman and CEO of NuProbe Global, stated“Over the past year, NuProbe Global has perfectly met expectations in technological innovation, system optimization, product development, and business expansion. We sincerely thank our new and existing investors for their trust and support. We will continue to leverage foundational technological innovations to create affordable, timely, and accurate market solutions, driving the routine adoption of genetic testing.”

Professor David Zhang, Co-founder of NuProbe Global, stated“NuProbe Global’s BDA technology significantly enhances the sensitivity, multiplexing capability, and cost-effectiveness of next-generation sequencing (NGS), quantitative PCR, and digital PCR. Meanwhile, our recently launched QASeq technology delivers optimal sensitivity for detecting copy number variations. We sincerely appreciate the continued support and enthusiasm from both new and existing investors. This new round of financing will enable us to better expand our collaborations with biopharmaceutical and molecular diagnostics companies, thereby delivering companion diagnostic products that positively impact the lives of cancer patients.”

Chen Bing, Managing Director of the AstraZeneca CICC Healthcare Industry Fund, Vice President of AstraZeneca China, and Head of Strategic Partnerships and Business Development, stated“AstraZeneca firmly believes that technological innovation is the primary driving force in the biopharmaceutical industry. China’s molecular diagnostics sector urgently requires the application of groundbreaking foundational technologies to address challenges related to complex clinical workflows, accuracy, and cost. As one of the few Chinese scientist teams capable of licensing their proprietary intellectual property to global life sciences giants, NuProbe Global has impressed us with its exceptional technical prowess and proactive corporate culture. We look forward to and are confident that liquid biopsy products developed based on NuProbe Global’s proprietary technologies will achieve success in both clinical application and commercialization.”

Shan Junbao, President of CICC Capital and Designated Representative of the Executive Partner of the AstraZeneca-CICC Healthcare Industry Fund, stated“Precision medicine relies on high-sensitivity detection technologies. NuProbe Global’s leading patented technologies empower a wide range of applications, from genetic testing for infertility and carrier screening for hereditary diseases to early cancer screening, companion diagnostics, and recurrence monitoring. This enables physicians to adopt appropriate diagnostic and treatment strategies, ultimately benefiting patients. We will fully support NuProbe Global’s development and look forward to the timely launch of more of its products to benefit patients.”

Zhou Yi, CEO of the China Resources Zhengda Life Sciences Fund, stated“Liquid biopsy is not only a developmental direction in medical diagnostics but, in some scenarios, even the sole method available. However, due to certain technical bottlenecks, it has not yet been effectively implemented in clinical practice. To unlock the potential of liquid biopsy, it is crucial to continuously enhance its sensitivity and specificity through innovative foundational technologies while ensuring affordability for the majority of patients. NuProbe Global’s patented technology platform effectively addresses these challenges, thereby laying a solid foundation for the true clinical application of liquid biopsy.”

Li Yuhui, Founding Managing Partner and Chairman of Panlin Capital, stated“NuProbe Global is an innovation-driven, international genomics company. Its core team represents a rare combination in China, possessing both strong R&D capabilities and robust commercialization expertise. As long-standing shareholders of NuProbe Global, we are delighted to witness the company’s continuous technological innovation and breakthroughs. By leading the industry with multiple revolutionary molecular diagnostic technologies and a platform-based product system that combines high sensitivity with cost-effectiveness, NuProbe Global has become a niche market leader in the blue-ocean sector of male infertility genetic testing. The founder, Mr. Chai, is a seasoned industry veteran. We believe that under his leadership and that of the management team, the company will emerge as a distinctive competitor in the oncology field during its next stage of development. We also look forward to NuProbe Global’s continued refinement and growth, aspiring to become an innovative leading enterprise in the molecular diagnostics sector in China and globally.”

Li Jin, Managing Director of China Renaissance, stated“NuProbe Global stands out as a prime example of the genetic testing companies that China Renaissance Capital has been closely monitoring—those with platform-based innovation capabilities and a global vision. The company has become the undisputed leader in the field of infertility, demonstrating its exceptional product strength. As its oncology-related product lines continue to be refined, NuProbe Global will further expand the potential for future business growth. We are honored to partner with NuProbe Global and witness firsthand the profound transformation that BDA and QASeq technologies are bringing to the genetic testing industry.”

Since 2021, NuProbe Global has entered a phase of rapid development. The company has continuously developed multiple revolutionary underlying molecular detection technologies and collaborated with renowned institutions such as the MD Anderson Cancer Center, Microsoft Research, and Shanghai Pulmonary Hospital. It has published nearly 10 research findings in top-tier international journals, including the Nature series, with a cumulative impact factor exceeding 120. As a leading enterprise in China’s genetic testing market for infertility, NuProbe Global maintains collaborative relationships with over 400 well-known reproductive health hospitals across China. Furthermore, it was selected as the exclusive technical support provider for the “Real-World Study and Database Construction on Male Reproductive-Related Genetic Testing in China,” a project involving 100,000 cases led by the Andrology Branch of the Chinese Medical Association.

In the field of tumor detection, NuProbe Global’s latest liquid biopsy products, developed based on its proprietary BDA and QASeq technologies, have demonstrated excellent clinical performance. The company has established collaborations with over 300 hospitals, experienced rapid business growth, and obtained EU CE certification for in vitro diagnostic reagents. Meanwhile, NuProbe Global has built close cooperative and development relationships with internationally leading technology companies such as BioNano and C2i Genomics. In 2021, NuProbe Global achieved dual certification for ISO 9001 and ISO 13485 quality management systems, secured a Class III medical device operation license, and officially inaugurated its Suzhou R&D center and production base, marking a new phase of systematic, standardized, and regulated manufacturing. The company was successfully selected as a “China Potential Unicorn Enterprise” and received titles including Suzhou City’s Key “Listing Nursery” Enterprise, “Unicorn” Cultivation Enterprise, and “Gazelle” Cultivation Enterprise.

 Multiple Technical Papers Published by the Company in Top Core Journals in 2021

NuProbe Global is a technology innovation-driven global genomics company that possesses multiple revolutionary molecular diagnostic technologies. These technologies can reduce sequencing costs across all NGS platforms by more than 98% and increase the sensitivity of qPCR, Sanger, and nanopore sequencing by over 100-fold. NuProbe Global has established branches in Houston, USA; Shanghai, China; Suzhou, China; and Beijing, China. The company’s vision is to create affordable, timely, and accurate genetic analysis tools, working with numerous partners to advance precision medicine and improve patient outcomes.

AstraZeneca CICC Healthcare Industry Fund is a private equity fund jointly initiated by AstraZeneca and CICC Capital, focusing on investments in the healthcare industry. Leveraging AstraZeneca’s global industrial strengths and CICC Capital’s extensive experience in capital operations, the fund targets investment areas such as biopharmaceuticals, medical devices, diagnostic services, and digital health. It is committed to integrating industrial and financial resources to provide enterprises with full-cycle empowerment from research and development to commercialization, jointly fostering innovative development in China’s healthcare industry.

The CR Zheng Life Sciences Fund is a private equity fund jointly established by China Resources Group and Thailand’s Charoen Pokphand Group, focusing on investing in early-stage and growth-stage enterprises in the life sciences sector. The first phase of the fund has a size of USD 170 million. The fund invests in innovations within the global life sciences field to meet Chinese patients’ demand for innovative products, technologies, and services. The fund’s investment team possesses extensive management and investment experience in the broader healthcare sector, helping portfolio companies enhance the value of their operations in China.

Panlin Capital is an early-to-mid-stage venture capital firm focused on technological innovation, operating under the theme of “technological innovation driving consumption upgrades” and concentrating on the healthcare and technology sectors. In the healthcare domain, Panlin leverages biotechnology to focus on investing in innovative biopharmaceutical R&D for major diseases and enterprises developing high-end medical devices for import substitution. Its early-stage portfolio includes biopharmaceutical companies such as Kangtai Biological Products (300601), Ribo Life Science, Shengnuoji, Apollomics, GenFleet Therapeutics, QinheLi, Cothera, ABM, Fuhuo Jian, Jianxin Biologics, Jianxin Yuanli, and Codon; as well as medical device and service companies such as Hybribio (300639), Jinshi Biotech, Antai Kangcheng, TouchImaging, Langrui Medical, Omega Meditech, Beijing Children’s Hospital (Kyoto Children’s Hospital), Kaipu Medical Laboratory, NuProbe Global, and 3N Technology.

CFI Capital is a leading new-economy investment bank in China, focusing on three major sectors globally: TMT, consumer, and healthcare. Beyond its investment banking services, CFI Capital manages one RMB-denominated fund and one USD-denominated fund. The firm has branches in Beijing, Shanghai, Los Angeles, and San Francisco, and holds licenses to operate in the U.S. securities market. Healthcare is a key focus area where CFI Capital possesses deep expertise; it has been ranked for five consecutive years as the new-economy investment bank with the highest number of healthcare industry transactions in China. Meanwhile, CFI Capital boasts the largest, most professional, and most comprehensively integrated investment banking team dedicated to the healthcare industry in China.